Blood test for Parkinson's disease
Part of Brain & nervous system clinical trials.
This study is testing whether a simple blood test can help doctors better understand Parkinson's disease by looking at how a protein called alpha-synuclein behaves. It aims to find a new way to diagnose and track the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Parkinson's disease by a movement disorder specialist.
- You have primary Parkinson's disease (not caused by another condition or medication).
- You have not had brain surgery or deep brain stimulation (DBS) for Parkinson's.
- You do not have a diagnosis of dementia (mild memory problems are okay).
- You are willing to give a blood sample and complete questionnaires about your symptoms and daily life.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for a new blood marker that could help doctors detect Parkinson’s disease earlier. Depending on your diagnosis and treatment status, your blood may be compared with other people’s to see how well the test works.
This study examines changes in alpha-synuclein, a protein linked to Parkinson's, to better understand how the disease progresses. It may help researchers learn more about Parkinson's and improve future care.
This study measures blood biomarkers (measurable substances in blood) in people with Parkinson’s at different stages. It may help doctors understand how Parkinson’s changes over time and could guide future testing or treatments.
This study looks for new markers in the blood or other samples to help diagnose Parkinson's disease earlier. It compares people with Parkinson's, related conditions (like multiple system atrophy or progressive supranuclear palsy), and healthy volunteers to find differences.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This study looks for changes in a protein called alpha-synuclein in people who may be in the early “prodromal” stage before Parkinson’s symptoms fully appear. It may help researchers find early markers and understand who is more likely to develop Parkinson’s disease.
Hear when a new RT-QuIC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.